NCI Director’s Consumer Liaison Group Is Named
December 1st 1997BETHESDA, Md-Fifteen consumer advocates will form the first Director’s Consumer Liaison Group (DCLG) at the National Cancer Institute. Panel members, most of them cancer survivors, were selected from a pool of 136 candidates. They will serve 3-year terms on the new advisory board, which will hold its first meeting in December.
Use of Hematopoietic Hormones for Bone Marrow Defects in AIDS
December 1st 1997Aboulafia provides an extensive review of the occurrence of and treatments for bone marrow disorders that complicate HIV infection and AIDS. Understanding of the pathogenesis of these disorders is increasing, and the availability of recombinant colony-stimulating factors (CSFs) has, in many ways, facilitated the treatment of HIV-1 infection and its complications. Nonetheless, numerous critical questions remain regarding the optimal use of these expensive and powerful reagents.
Neuroblastoma: Biology and Therapy
December 1st 1997Neuroblastoma is a clinically heterogeneous disease which can have a benign, localized behavior or a rapidly progressive, widely disseminated, lethal character. In recent years, knowledge of tumor biology-genetic changes and other biological markers-has allowed for reliable prediction of patient outcomes. These markers, when combined with clinical staging and histologic findings, determine the relative risk for a given patient and allow therapy to be tailored to that particular level of risk.
Indolent B-Cell Non-Hodgkin’s Lymphomas
December 1st 1997B-cell non-Hodgkin’s lymphomas (NHL) are an increasingly common cause of cancer morbidity and mortality. In 1996, approximately 52,700 new cases of NHL were diagnosed, representing a marked increase in incidence. Indeed, the incidence rose from 8.5 per 100,000 population in 1973 to 15.1 per 100,000 in 1992.[1] About 20% to 30% of these are NHLs of the indolent varieties.
Promoting Smoking Cessation Among Cancer Patients: A Behavioral Model
December 1st 1997The article, Promoting Smoking Cessation Among Cancer Patients, is an excellent complement to the clinical practice guideline on smoking cessation recently published by the Agency for Health Care Policy and Research (AHCPR).[1] The guideline presented considerable detail for clinicians on how to help smokers who are prepared to quit. For the approximately 80% of smokers who are not prepared, the guideline included only a few paragraphs. The approach of Prokhorov, Hudman, and Gritz, seasoned clinicians and scientists, can help clinicians become much more confident when counseling all smokers, including those in the precontemplation and contemplation stages.
Use of Hematopoietic Hormones for Bone Marrow Defects in AIDS
December 1st 1997Anemia is a common complication of HIV infection. Erythropoietin (Procrit, Epogen) can correct anemia. When given to patients with HIV infection, erythropoietin ameliorates anemia and improves quality of life. Given these three facts, one wonders why an effective drug such as erythropoietin is not used appropriately in patients with HIV infections.
Neuroblastoma: Biology and Therapy
December 1st 1997Neuroblastoma is the most common solid extracranial tumor in children. Although the outcome of patients with localized disease has improved substantially, the prognosis for those with advanced disease is still poor, despite multimodality therapeutic efforts of increasing intensity over the last 20 years. Dr. Matthay provides an excellent overview review of the biology and treatment of this devastating but fascinating childhood malignancy.
Use of Hematopoietic Hormones for Bone Marrow Defects in AIDS
December 1st 1997Bone marrow suppression is a substantial problem in patients infected with HIV. Contributing factors include the underlying HIV infection, alterations in the marrow microenvironment (resulting in abnormal cytokine regulation
Roswell Park Cancer Institute Plans Spring 1998 Move to its New Campus
December 1st 1997BUFFALO, NY-In 1998, the year of its 100th anniversary celebration, Roswell Park Cancer Institute will move into its new $241 million campus, including a new hospital building (see photograph) and major renovations.
Campaign Launched to Improve Awareness of Mammography
December 1st 1997WASHINGTON-President Clinton, with Mrs. Clinton joining him, highlighted a three-pronged effort to ensure that women over age 40 have information about and access to regular and high-quality mammograms. The Clintons spoke during one of the President’s regular Saturday morning radio broadcasts.
NCI Starts New Program to Investigate HIV Resistance
December 1st 1997BETHESDA, Md-The National Cancer Institute has established a program to investigate drug resistance in the AIDS virus. NCI director Richard D. Klausner, MD, told the National Cancer Advisory Board (NCAB) that the new effort will cut across NCI’s intramural program and that he expects it to involve extramural researchers and scientists from other institutes within the National Institutes of Health.
Oral Regimens Prevent Most Chemo-Induced Emesis
December 1st 1997NEW ORLEANS-It is possible to prevent most cases of chemotherapy-induced emesis by simple, convenient, and cost-effective regimens, Richard J. Gralla, MD, director of the Ochsner Foundation Cancer Institute, New Orleans, said at a cancer update sponsored by the Ochsner Medical Foundation and the American Cancer Society.
Agenda for NCI’s New Cancer Control Division
December 1st 1997BETHESDA, Md-The National Cancer Institute’s mint-new Division of Cancer Control and Population Science got its marching orderings only days before officially beginning operations. The National Cancer Advisory Board (NCAB) accepted the recommendations of a committee report titled “A New Agenda for Cancer Control Research” as a basic operating plan for the division.
Private Sector Purchasers Need Cancer Care Data to Determine Quality
November 1st 1997CHICAGO-Health care professionals who provide care to cancer patients need to help managers of employee benefits programs determine the cost and quality of the oncology services they purchase, said Dale Orred, corporate benefits manager for United Parcel Service, Atlanta.
Payers May Ignore Aspects of Care Most Important to Patients
November 1st 1997CHICAGO-As the health care system in this country shifts from fee for service to managed care, private and public payers are being forced to make decisions about the oncology services they purchase. As payers struggle to define the scope of their coverage of oncology services, however, they may be ignoring the aspects of care that are most important to patients, speakers said at a conference on purchasing oncology services, sponsored by the American Cancer Society.
‘Treat Low-risk Febrile Neutropenic Patients at Home’
November 1st 1997TORONTO-Cancer patients with febrile neutropenia have routinely been hospitalized and treated with intravenous antibiotics. A pilot study presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) suggests that low-risk patients can be treated just as well at home.
‘Don’t Wait Too Late to Make End-of-Life Decisions’
November 1st 1997BROOKVILLE, NY-“Most of us wait until it’s too late to make decisions on end-of-life care,” Robert C. Cassidy, PhD, said at a conference on that subject. “But somewhere out there is an abyss, and we better start knitting a parachute before we get pushed out of the plane.”
Federation of European Cancer Societies Sponsors Biennial ECCO
November 1st 1997HAMBURG-More than 6,000 cancer researchers, clinical oncologists, and specialist cancer nurses from all over the world attended the Ninth European Cancer Conference (ECCO 9), considered Europe’s foremost multidisciplinary oncology event. (See reports on pages 1, 2, 3, 8, 13, 15, 24, 27, and 40.)
FDA Reform Bill in Congressional Committee
November 1st 1997WASHINGTON-The House and Senate have each passed bills revising the process by which the Food and Drug Administration approves new drugs and medical devices. But what happens in the conference committee that resolves a significant difference between the two measures may well decide whether President Clinton signs or vetoes the final bill.
Higher Quadramet Dose Produces Better Bone Pain Relief
November 1st 1997n PRINCETON, NJ-A single dose of Quadramet (Samarium Sm 153 Lexidronam injection) significantly relieved bone pain in patients with metastatic breast, prostate, and other primary cancers in a dose-dependent manner, a multicenter European study has shown.
‘Survival’ of Private Practice Medical Oncologists at Risk
November 1st 1997CHICAGO-“Is the private practice oncologist at risk? I think we are,” said Bruce Feinberg, DO, at the first national conference on purchasing oncology services, sponsored by the American Cancer Society and the Kerr L. White Institute for Health Services Research, Decatur, Ga.
Court Decision Forces MDs to Keep Assisted Suicides Secret
November 1st 1997CHICAGO-When the US Supreme Court decided recently that patients have no inherent right to physician-assisted suicide, it neglected to help physicians decide how to respond to those “exceptional cases involving real patients with real suffering,” said Timothy E. Quill, MD, at the American Academy of Family Physicians annual meeting.
ACS to Make Recommendations on Purchasing Cancer Services
November 1st 1997CHICAGO-The purchasers that make critical health care decisions for approximately 75% of the American population who have insurance readily acknowledge they have little understanding of the cost of oncology care or the types of services that cancer patients need.
Intrathecal SNX-111 Reduces Intensity of Chronic Cancer Pain
November 1st 1997BARCELONA, Spain-Intrathecal administration of the selective neuronal channel blocker SNX-111 via an external pump proved safe and feasible in 11 patients with chronic intractable pain. More than half of the group saw an improvement in pain control, William Brose, MD, reported at a meeting of the International Association for the Study of Pain.